Table 4.
Treatments | Exploration time (seconds) | Discrimination index | ||
---|---|---|---|---|
Session 1 | Session 2 | |||
N | F | |||
H2O + Scop | 31.4 ± 2.1 | 21.2 ± 0.64c | 18 ± 1.2c | 0.08c |
39.3 + Scop | 38.2 ± 1.8 | 36.2 ± 3.0∗∗∗ | 13.8 ± 0.7∗∗ | 0.45∗ |
98.25 + Scop | 34.8 ± 2.6 | 38.0 ± 1.6∗∗∗ | 11.4 ± 1.3∗∗∗ | 0.54∗∗∗ |
196.5 + Scop | 38.0 ± 3.6 | 40.2 ± 3.0∗∗∗ | 9.6 ± 1.9∗∗∗ | 0.61∗∗∗ |
393 + Scop | 32.0 ± 3.2 | 32.0 ± 2.8∗∗∗ | 10.8 ± 1.4∗∗∗ | 0.49∗∗ |
Pira + Scop | 33.0 ± 2.8 | 35.4 ± 2.5∗∗∗ | 11.8 ± 1.5∗∗∗ | 0.50∗∗∗ |
H2O + H2O | 30.0 ± 1.6 | 36.0 ± 3.6∗∗∗ | 11.2 ± 1.1∗∗∗ | 0.52∗∗∗ |
Data are mean ± SD, n = 5 per dose. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001, compared to scopolamine-treated group (H2O + Scop), one-way ANOVA followed by Dunnett's bilateral comparisons for exploration time, and Duncan's test for discrimination index. cP < 0.001 compared to normal control group (H2O + H2O), one-way ANOVA followed by Dunnett's bilateral comparisons for exploration time, and Duncan's test for discrimination index. F: familiar object, H2O: distilled water, N: novel object, Pira: piracetam 200 mg/kg, Scop: scopolamine 0.4 mg/kg.